MetaVia Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
39.1%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$2.49next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| DA-1726 Phase 1 Part 3 Data Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
DA-1726 Phase 1 Part 3 Clinical Trial Progress QuarterlyTarget: Dosing of titration cohorts to evaluate one-step dose titration to 48 mg and two-step dose titration to 64 mg
DA-1726 Phase 1 Part 3 Data Readout QuarterlyTarget: Top-line data readout for Part 3a and Part 3b
Vanoglipel (DA-1241) Phase 2a Clinical Study Report (CSR) Finalization QuarterlyTarget: Finalize the CSR of the Phase 2a trial in patients with presumed MASH
Watch Items
- Nasdaq Minimum Bid Price Requirement ComplianceTrigger: Share price below $1.00 for consecutive trading daysAction: Implement the approved reverse stock split at a ratio in the range of 1-for-5 to 1-for-22 at the discretion of the Board of Directors to raise the per-share market price
- Financial Runway and Cash Burn RateTrigger: Cash and cash equivalents falling below levels required to fund operations for the next quarterAction: Monitor cash reserves ($13.7 million as of March 31, 2026) and evaluate potential capital raising or strategic milestone-based warrant exercises
Research as of 20 Jun 2026